Novartis and Alcon - Top 10 deals of 2008

Novartis and Alcon are awarded the Top Deal of 2008 for Novartis' acquisition of Alcon.Who: Novartis
With: Alcon
What: $39B acquisition

Summary: Novartis pledged $39 billion for the eye care company Alcon in a move to diversify its business operations. Novartis bought a 25 percent stake in Alcon and could purchase another 52 percent in 2010. CEO Daniel Vasella said the purchase was a good fit and that the eye care market is growing as the population ages. Additionally, he observed, there's a lack of pricing pressure on eye products. While insurers and the government are twisting drugmakers' arms for discounts, consumers usually pay out of pocket for the kind of eye-care products Alcon sells.

Novartis and Alcon - Top 10 deals of 2008

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i